论文部分内容阅读
目的:探讨沙美特罗替卡松联合芪蛤止哮胶囊治疗咳嗽变异性哮喘的临床疗效及安全性。方法:将128例咳嗽变异性哮喘患者随机分为治疗组和对照组。治疗组64例予沙美特罗替卡松联合芪蛤止哮胶囊治疗;对照组64例予沙美特罗替卡松治疗。两组均以28 d为1个疗程,连续治疗2个疗程,并随访4个月。比较两组临床疗效及复发情况。结果:治疗组总有效率为90.6%,对照组总有效率为76.6%,治疗组优于对照组,差异有统计学意义(P=0.032);两组患者治疗后相关肺功能指标均较治疗前明显提高,差异有统计学意义(P<0.05);治疗组相关肺功能指标改善均优于对照组,差异有统计学意义(P<0.05);治疗组复发率低于对照组,差异有统计学意义(P=0.006);两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论:沙美特罗替卡松联合芪蛤止哮胶囊治疗咳嗽变异性哮喘有较好疗效,可改善患者肺功能,复发率低。
Objective: To investigate the clinical efficacy and safety of salmeterol and ticalaprost in combination with Qizhi Zhixiao Capsule in the treatment of cough variant asthma. Methods: 128 cases of cough variant asthma patients were randomly divided into treatment group and control group. Sixty-four patients in the treatment group were treated with salmeterol and fluticasone in combination with Qizhi Zhixiao Capsule. The control group was treated with salmeterol and fluticasone in 64 patients. Both groups were 28 days for a course of treatment for two courses of continuous treatment, and followed up for 4 months. The clinical efficacy and recurrence of the two groups were compared. Results: The total effective rate was 90.6% in the treatment group and 76.6% in the control group. The treatment group was superior to the control group with statistically significant difference (P = 0.032). The lung function indexes of the two groups were significantly higher than those of the treatment group (P <0.05). The improvement of pulmonary function indexes in the treatment group was better than that in the control group, the difference was statistically significant (P <0.05); the recurrence rate of the treatment group was lower than that of the control group, the difference was Statistical significance (P = 0.006); There was no significant difference between the two groups in the occurrence of adverse reactions (P> 0.05). CONCLUSIONS: Salmeterol / fluticasone combined with Qimizhizhuo Capsule has a good curative effect on cough variant asthma, which can improve the lung function and the low recurrence rate.